Immunotherapy breakthrough now approved as standard of care for advanced melanoma

A first-of-its-kind (anti-PD-1) immunotherapy was recently approved by the U.S. Food & Drug Administration as first-line treatment for metastatic melanoma--allowing greater access to this therapy for patients without having to previously receive other prior treatments.